Recalcitrant cutaneous warts treated with recombinant quadrivalent human papillomavirus vaccine (types 6, 11, 16, and 18) in a developmentally delayed, 31-year-old white man

Archives of Dermatology

Volumn 146, Issue 5, 2010, Pages 475-477

  Venugopal, Supriya S ^a   Murrell, Dedee F ^a  

^a UNIVERSITY OF NEW SOUTH WALES   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

CIMETIDINE; IMIQUIMOD; PODOPHYLLIN; SALICYLIC ACID; WART VIRUS VACCINE;

ADULT; ARTICLE; CASE REPORT; CRYOTHERAPY; DEVELOPMENTAL DISORDER; DRUG EFFICACY; EVENING DOSAGE; HUMAN; HUMAN PAPILLOMAVIRUS TYPE 11; HUMAN PAPILLOMAVIRUS TYPE 16; HUMAN PAPILLOMAVIRUS TYPE 18; HUMAN PAPILLOMAVIRUS TYPE 6; HYPERKERATOSIS; MALE; PRIORITY JOURNAL; VERRUCA VULGARIS;

ADULT; CHILD; DEVELOPMENTAL DISABILITIES; HUMANS; MALE; PAPILLOMAVIRUS INFECTIONS; PAPILLOMAVIRUS VACCINES; RISK FACTORS; WARTS;

EID: 77952641176     PISSN: 0003987X     EISSN: 15383652     Source Type: Journal    
DOI: 10.1001/archdermatol.2010.71     Document Type: Article

References (10)

1. Villa LL, Costa RL, Petta CA, et al. High sustained efficacy of a prophylactic quadrivalent human papillomavirus types 6/11/16/18 L1 virus-like particle vaccine through 5 years of follow-up. Br J Cancer. 2006;95(11):1459- 1466.
2. FUTURE II Study Group. Prophylactic efficacy of a quadrivalent human papillomavirus (HPV) vaccine in women with virological evidence of HPV infection. J Infect Dis. 2007;196(10):1438-1446.
3. Markowitz LE, Dunne EF, Saraiya M, et al; Advisory Committee on Immunization Practices (ACIP). Quadrivalent human papillomavirus vaccine: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep. 2007;56(RR-2):1-24.
4. Schiller JT, Castellsagué X, Villa LL, Hildesheim A. An update of prophylactic human papillomavirus L1 virus-like particle vaccine clinical trial results. Vaccine. 2008;26(suppl 10):K53-K61.
5. Rivera A, Tyring SK. Therapy of cutaneous human papillomavirus infections. Dermatol Ther. 2004;17(6):441-448. (Pubitemid 39657276)
6. Albarran Y Carvajal A, de la Garza A, Cruz Quiroz BJ, et al. MVA E2 recombinant vaccine in the treatment of human papillomavirus infection in men presenting intraurethral flat condyloma: a phase I/II study. BioDrugs. 2007;21(1):47-59.
7. Ault KA. Human papillomavirus vaccines and the potential for cross-protection between related HPV types. Gynecol Oncol. 2007;107(2)(suppl 1):S31-S33. (Pubitemid 47552539)
8. Slupetzky K, Gambhira R, Culp TD, et al. A papillomavirus-like particle (VLP) vaccine displaying HPV16L2 epitopes induce cross-neutralizing antibodies to HPV11. Vaccine. 2007;25(11):2001-2010. (Pubitemid 46227679)
9. Pinto LA, Viscidi R, Harro CD, et al. Cellular immune responses to HPV-18,-31, and -53 in healthy volunteers immunized with recombinant HPV-16 L1 virus like particles. Virology. 2006;353(2):451-462.
10. Harper DM, Franco EL, Wheeler CM, et al; HPV Vaccine Study group. Sustained efficacy up to 4.5 years of a bivalent L1 virus-like particle vaccine against human papillomavirus types 16 and 18: follow up from randomised control trial. Lancet. 2006;367(9518):1247-1255.